Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 3/20 | 0.44 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | F9 | P00740 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6579110 | 0.86 | F2 (0.56) | F10F2ABCG2 | |
| SCHEMBL8875195 | 0.85 | SYK (0.46) | SYKCDC7EGFRABCG2SLC2A1 | |
| SCHEMBL6578699 | 0.82 | F2 (0.50) | SYKF10F2ABCG2 | |
| SCHEMBL6576366 | 0.81 | SYK (0.61) | SYKF10CDC7EGFRABCG2 | |
| SCHEMBL6581479 | 0.76 | F10 (0.64) | F10F2 | |
| SCHEMBL6576962 | 0.74 | F10 (0.64) | SYKF10F2CDC7EGFR | |
| SCHEMBL8336523 | 0.70 | SYK (0.46) | SYKF10CDC7EGFRABCG2 | |
| SCHEMBL8336524 | 0.70 | SYK (0.46) | SYKF10CDC7EGFRABCG2 | |
| SCHEMBL7686054 | 0.68 | MAPT (0.37) | F10F2 | |
| SCHEMBL655532 | 0.66 | SYK (1.00) | SYKCDC7EGFRCDK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0813525-B9 | BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS | BERLEX LAB (US) | 2004-02-04 | — | — | EP | disclosed |
| US-6686364-B2 | 4-HYDROXY-3-((3,5-DIFLUORO-6-(3 -DIMETHYLAMINOCARBONYLPHENOXY)-4-(2-METHOXY-4-CARBOXYPHENOXY) PYRIDIN-2-YL)OXY)BENZAMIDINE, FOR EXAMPLE; FACTOR XA INHIBITORS | BERLEX LABORATORIES, INC. | 2004-02-03 | — | — | US | disclosed |
| EP-0813525-B1 | BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS | BERLEX LAB (US) | 2003-10-01 | — | — | EP | disclosed |
| US-6479485-B2 | 4-HYDROXY-3-((3,4-DIFLUORO-6-(3 -DIMETHYLAMINOCARBONYLPHENOXY)-4-(2-METHOXY-4-CARBOXYPHENOXY) PYRIDIN-2-YL)OXY)BENZAMIDINE, FOR EXAMPLE; INHIBITION OF BLOOD COAGGULATION FACTOR XA | BERLEX LABORATORIES, INC. | 2002-11-12 | — | — | US | disclosed |
| US-6465459-B2 | INHIBIT THE ENZYME, FACTOR XA | BERLEX LABORATORIES, INC. | 2002-10-15 | — | — | US | disclosed |
| US-20020035109-A1 | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. | 2002-03-21 | — | — | US | disclosed |
| US-20020032223-A1 | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. | 2002-03-14 | — | — | US | disclosed |
| US-20020028820-A1 | Benzamidine derivatives and their use as anti-coagulants | BERLEX LABORATORIES, INC. | 2002-03-07 | — | — | US | disclosed |
| US-6350746-B1 | FACTOR XA ENZYME INHIBITORS | BERLEX LABORATORIES, INC. | 2002-02-26 | — | — | US | disclosed |
| US-6306884-B1 | ANTICOAGULANTS AND BLOOD COAGULATION FACTOR | BERLEX LABORATORIES, INC. | 2001-10-23 | — | — | US | disclosed |
| US-6034103-A | THROMBOSIS THERAPY | BERLEX LABORATORIES, INC. (US) | 2000-03-07 | — | — | US | disclosed |
| US-6004981-A | HUMAN FACTOR XA INHIBITORS | BERLEX LABORATORIES, INC. | 1999-12-21 | — | — | US | disclosed |
| EP-0813525-A1 | BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| WO-1996028427-A1 | BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032223-A1 | Benzamidine derivatives and their use as anti-coagulants | SERPINC1, HABP2, SERPINE1 | SYK 1329/4885F10 44/4885F2 4/4885 |
| US-20020028820-A1 | Benzamidine derivatives and their use as anti-coagulants | SERPINC1, HABP2, SERPINE1 | SYK 1329/4885F10 44/4885F2 4/4885 |
| US-20020035109-A1 | Benzamidine derivatives and their use as anti-coagulants | SERPINC1, HABP2, SERPINE1 | SYK 1307/4885F10 49/4885F2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.